277 results about "Bacterosira" patented technology

The invention belongs to the technical field of microorganisms, and particularly relates to bifidobacterium animalis for relieving eye allergy and application of the bifidobacterium animalis. The invention provides an application of bifidobacterium animalis subsp. Lactis in preparation of a product for relieving eye allergy, the bifidobacterium animalis subsp. Lactis is Def +, and the preservation number is CGMCC (China General Microbiological Culture Collection Center) No.35798. The Bifidobacterium animalis subsp. Lactis Def < + > provided by the invention can relieve the eye itching symptom, relieve red and swollen eyelids, reduce conjunctiva and cornea injury, relieve eye discomfort, relieve globular conjunctivitis cell infiltration, improve corneal epithelium thickening lesion, improve the anti-inflammatory ability and improve allergic conjunctivitis, keratitis and blepharitis marginata in a targeted manner. The eye drops are high in safety and resistant to gastrointestinal fluid, and a safe and long-acting scheme is provided for eye allergic diseases.

The invention discloses an application of an antibacterial peptide and an application of the antibacterial peptide in preparation of antibacterial drugs for treating carbapenem-resistant pseudomonas aeruginosa, klebsiella pneumoniae (ATCC700603), escherichia coli (ATCC25922), staphylococcus aureus and methicillin-resistant staphylococcus aureus, the antibacterial peptide is characterized in that the sequence is w-r-r-w-k-r-w-w-r-r, and the sequence is shown in the description. All amino acids are D-type amino acids; the antibacterial peptide can be used as an antibacterial substance in wash supplies, food preservative additives, medical consumable antibacterial agents and cosmetics, can be synthesized through an Fmoc solid-phase chemical method, and is low in synthesis difficulty and good in in-vivo antibacterial activity. Particularly, the antibacterial peptide has broad-spectrum killing activity against carbapenem pseudomonas aeruginosa, klebsiella pneumoniae (ATCC700603), escherichia coli (ATCC25922), staphylococcus aureus and methicillin-resistant staphylococcus aureus, the cell survival rate of the antibacterial peptide within the range of medium and low concentration (2 mu g / mL-32 mu g / mL) reaches half or more, the toxicity is small, the toxicity is almost avoided, the operability is high, and the antibacterial peptide can be widely applied to the field of medical application. The cost is low.

The invention belongs to the technical field of antibacterial peptides, and particularly relates to an antibacterial peptide Mh-GC21 as well as a precursor and application thereof. The amino acid sequence of the antibacterial peptide Mh-GC21 provided by the invention is as shown in SEQ ID NO.1, and two cysteines are oxidized to form a pair of intermolecular disulfide bonds; the C tail end of the antibacterial peptide Mh-GC21 is subjected to amidation modification. The antibacterial peptide Mh-GC21 provided by the invention is from microhyla microcarpa, has broad-spectrum antibacterial activity, has relatively good antibacterial and bactericidal effects on standard strains of acinetobacter baumannii, escherichia coli and staphylococcus aureus and clinically sourced drug-resistant strains, and can be used for targeted destruction of cell membranes of bacteria, removal of biological membranes and inhibition of formation of the biological membranes. Moreover, the antibacterial peptide Mh-GC21 has the advantages of good stability, no hemolytic activity and cytotoxicity, and difficulty in inducing strains to generate drug resistance.

The invention belongs to the technical field of microorganisms, and particularly relates to application of bifidobacterium longum in preparation of products for prevention, treatment and / or adjuvant treatment of pneumonia. The preservation number of the bifidobacterium longum is GDMCC No: 65969, and the bifidobacterium longum can improve the body weight decrease trend of a pneumonia mouse and reduce the lung visceral organ index of LPS increase; the content of pro-inflammatory factors such as IL-1beta, TNF-alpha and IL-6 in serum is remarkably reduced, mRNA expression of inflammation-related genes such as COX-2, IFN-gamma and TNF-alpha in lung tissue is reduced, and dose dependence is achieved; meanwhile, alveolar structure damage and inflammatory cell infiltration of mouse lung tissue are relieved, and lung tissue pathological damage is repaired. The strain can be used as a core component for developing pneumonia prevention or adjuvant therapy related products, provides a novel microbial intervention means for pneumonia prevention and treatment, and has important application value.

The invention discloses a screening and expression platform construction method for non-essential gene loci of corynebacterium glutamicum, and belongs to the technical field of biology. The center sites CGLRS02940, CGLRS03085, CGLRS08555, CGLRS09020 and CGLRS13560 of the corynebacterium glutamicum identified by the invention have the remarkable advantages that when gene knockout or knockin operation is carried out, the sites do not interfere with the normal physiological metabolism process of strains, and stable expression of exogenous genes can be guaranteed; meanwhile, the gene editing efficiency is relatively high, and an editing target with high universality and high reliability is provided for genetic engineering modification of corynebacterium glutamicum.

The invention discloses a strain of Bacteroides ovatus L2 and application of the strain of Bacteroides ovatus L2 in a product for preventing and treating vomitoxin toxicity. The strain is preserved in Guangdong Microbiological Culture Collection Center, the preservation number is GDMCC.No: 67205, and the preservation date is November 4, 2025. The strain is separated and purified from a healthy adult excrement sample, has the characteristics of good acid resistance, cholate resistance, gastrointestinal fluid resistance and the like, and is free of hemolysis and good in safety. The strain can effectively relieve the toxic effect induced by vomitoxin, mainly inhibits inflammatory factors and promotes expression of intestinal barrier functional proteins, can be applied to products of microecologics for preventing and treating DON toxicity, and has a good application prospect.

The present application belongs to the field of microbial technology, and particularly relates to a bacteriophage preparation for controlling foodborne enterobacter and application thereof, wherein the bacteriophage preparation comprises any one or several of bacteriophage PhiEAS1, bacteriophage PhiEHO11, bacteriophage PhiEHO14 and bacteriophage PhiECL22. The four bacteriophages provided by the present application can be used alone or combined into a bacteriophage cocktail, and the influence of the bacteriophage preparation on enterobacter in different ecologies and environments is explored through bacteriophage cocktail therapy. The results show that the bacteriophage preparation exhibits significant bacteriostatic activity on various food substrates contaminated by Enterobacter hormaechei, such as lettuce, pork, milk, cherry tomato and the like; in an animal model, intraperitoneal injection of the bacteriophage preparation can effectively prevent and treat bacteremia caused by Enterobacter hormaechei, and shows potential as an anti-Enterobacter hormaechei biological control agent.

The invention belongs to the technical field of beverage mixing equipment, and particularly discloses a bifidobacterium beverage for regulating intestinal flora and mixing equipment, the bifidobacterium beverage comprises a bifidobacterium microbial inoculum, prebiotics, a base material and water; the equipment comprises a mixing tank, a rotating frame is rotationally arranged in the mixing tank, rotating blades are rotationally arranged on the rotating frame in the radial direction, a fixing shaft is arranged in the mixing tank, an end face fluted disc is arranged on the fixing shaft, and the ends, facing the center of the fixing shaft, of the rotating blades are meshed with the end face fluted disc; when the rotating frame rotates, the rotating blades synchronously rotate, and the composite motion of the rotating blades can fully cover conical areas at the upper end and the lower end of the mixing tank, so that a material deposition layer is effectively broken, and the problem of non-uniform component distribution caused by mixing dead angles of existing equipment is solved; meanwhile, the motion mode of composite stirring is milder, the local shear force can be obviously reduced, the inactivation of bifidobacterium cells due to mechanical damage is avoided, and the mixing efficiency and bacterial activity protection are both considered.

The invention discloses a novel acinetobacter baumannii phage vBAbaMpha0264 and application thereof, and belongs to the technical field of microorganisms. The acinetobacter baumannii phage vBAbaMpha0264 is preserved in the Guangdong Microbiological Culture Collection Center on August 28, 2025, the preservation number of the acinetobacter baumannii phage vBAbaMpha0264 is GDMCC (China General Microbiological Culture Collection Center) NO: 66893-B1, and the preservation address of the acinetobacter baumannii phage vBAbaMpha0264 is Institute of Microbiology, Academy of Sciences, Guangdong. The bacteriophage vBAbaMpha0264 has high cracking activity, environmental stability and safety, shows a breakthrough host range, and can be used for effectively cracking a plurality of acinetobacter bacteria including hospital acinetobacter and acinetobacter sysei. Meanwhile, the bacteriophage has excellent chloroform tolerance, and the stability of the bacteriophage is obviously superior to that of the existing bacteriophage. Due to the characteristics, the phage vBAbaMpha0264 overcomes the technical prejudice of'narrow spectrum and instability 'of the traditional phage, and a brand new technical scheme is provided for developing a universal antibacterial preparation covering more pathogenic bacteria.

The invention discloses bifidobacterium longum subsp. Infantis for regulating intestinal motility and aquaporin and application of the bifidobacterium longum subsp. Infantis, and belongs to the technical field of microorganisms. According to the invention, the bifidobacterium longum subsp. Infantis CCFM1269 is screened, and the bifidobacterium longum subsp. Infantis CCFM1269 has the effects of intestinal motility and aquaporin, specifically, the defecation frequency is reduced, and the water content of excrement and the small intestine propulsion rate are reduced. The intestinal motility abnormality is relieved by reducing the levels of neurotransmitters 5-HT, SP and VIP, and the intestinal moisture absorption and secretion are regulated by improving the mRNA expression of aquaporin AQP4 and AQP8. Meanwhile, the intestinal flora is adjusted by improving the diversity of the intestinal flora, and the content of propionic acid and butyric acid in excrement is increased.

The invention belongs to the technical field of medicines, and particularly relates to an aryl dicarboxylic acid compound, a preparation method and application of the aryl dicarboxylic acid compound as an antibacterial agent. The compound is shown as a formula (1), wherein R1, R2, R3, R4, R5, R6, R7, R8, R9 and R10 are independently selected from hydrogen and halogen. Two ends of the molecule are connected through an N-phenylpropanamide connecting arm, the molecule is a compound with a novel structure, and the series of compounds have a relatively strong inhibition effect on acinetobacter baumannii and are worthy of further research and development.

This invention discloses a strain of *Bifidobacterium pseudosporidis*, its preparation method, and its application in the prevention and treatment of METH addiction. *Bifidobacterium pseudosporidis* was isolated from fecal samples of individuals with low levels of METH addiction, and its strain identity was confirmed after isolation, purification, and identification. A METH addiction model was constructed by gavage colonization of C57 mice with this strain, and addiction-related indicators were detected in the model mice. The results showed that compared with the addiction model mice without colonization of this strain, the conditioned place preference score of the colonized group was significantly reduced (P<0.05). This *Bifidobacterium pseudosporidis* has a significant effect on improving METH addictive behavior and can be used to prepare biological agents with preventive and / or therapeutic functions for METH addiction. This invention reveals that *Bifidobacterium pseudosporidis* has the advantages of high safety and strong targeting, and can achieve the prevention and intervention of METH addiction without complex treatment equipment, providing a novel biological treatment option for the clinical treatment of METH addiction.

This invention relates to the fields of microbial genetic engineering and fermentation biomanufacturing technology, specifically disclosing a recombinant Corynebacterium glutamicum with high 5-aminolevulinic acid (ALA) production and its applications. Addressing the problems of existing strains such as crude enzyme activity regulation, inhibited cell growth, the need for external inhibitors, and low yield, this invention uses Corynebacterium glutamicum as a host and removes the gdhA gene without scarring to reduce precursor competitive metabolism. Site-directed mutations of the endogenous hemB gene (S288A, D128E, R231K) are performed to moderately reduce dehydratase activity. A high-expression plasmid pXMJ19-hemA containing the hemA gene from Rhodopsinus capsulatum is constructed and introduced into the modified strain to obtain a recombinant strain with optimized triple metabolism. This strain reduces product degradation without the need for external dehydratase inhibitors, does not affect cell growth, and achieves a yield up to 4.30 times higher than the control after 42 hours of fermentation, with ALA accumulation exceeding 8.9 g / L. The strain exhibits stable characteristics, the process is simple, and it has good industrial application value.

The invention relates to the technical field of biological pharmacy, and particularly discloses application of antibacterial small molecule peptide in preparation of antibacterial infection drugs. The antibacterial small molecule peptide is VeAMP, and the amino acid sequence of the antibacterial small molecule peptide is MKIVKRILLVL-NH2. The small molecule peptide VeAMP provided by the invention shows remarkable antibacterial activity on pan-drug-resistant acinetobacter baumannii, has the advantages of rapid sterilization, low hemolysis, low cytotoxicity and good in-vivo safety, is not easy to induce bacterial drug resistance after being exposed for a long time at a sub-inhibitory concentration, can effectively reduce tissue bacterial load, remarkably improves the survival rate of infected mice, and has a good application prospect. The invention provides a novel and safe candidate antibacterial agent which is not easy to generate drug resistance for preventing and treating drug-resistant acinetobacter baumannii infection.

The application provides a compound microbial agent for preventing and treating bacterial diseases of fruits and vegetables and a preparation method thereof, wherein the compound microbial agent comprises Brevibacillus brevis, Pseudomonas chlororaphis and Streptomyces; wherein the ratio of the viable bacterial count of the Brevibacillus brevis, the Pseudomonas chlororaphis and the Streptomyces is (1-3):(2-4):(1-2). The Brevibacillus brevis directly inhibits bacteria by secreting antibacterial peptides, the Pseudomonas chlororaphis competes for ecological niches through iron carriers, and the Streptomyces produces antibiotics, so that multiple strains form a "bacteriostasis-competition-immune activation" multiple mechanism, thereby achieving efficient prevention and treatment of bacterial diseases of fruits and vegetables.

The application belongs to the technical field of antibacterial peptides, and particularly relates to an antibacterial peptide Mp-GC21, a precursor thereof and application. The amino acid sequence of the antibacterial peptide Mp-GC21 is shown as SEQ ID NO:1, wherein the C terminal is subjected to amidation modification, and two cysteines are connected through a disulfide bond; and the amino acid sequence of the precursor is shown as SEQ ID NO:3. The antibacterial peptide Mp-GC21 is separated from the flower frog, has broad-spectrum antibacterial activity, and has good bacteriostatic and bactericidal effects on standard strains and clinically derived drug-resistant strains of Acinetobacter baumannii, Escherichia coli and Staphylococcus aureus, and can target to destroy the cell membrane of bacteria, remove the biofilm and inhibit the formation of the biofilm. Moreover, the antibacterial peptide Mp-GC21 has good stability, does not have hemolytic activity, cytotoxicity and in-vivo toxicity, and is not easy to induce drug resistance of strains.

The invention relates to the technical field of bacteriophages, and particularly discloses an acinetobacter baumannii bacteriophage, depolymerases and a preparation method and application of the acinetobacter baumannii bacteriophage. The acinetobacter baumannii bacteriophage P919 provided by the invention has very strong specific lysis capability on KL3 type acinetobacter baumannii, and the coded depolymerases of the acinetobacter baumannii bacteriophage P919 have excellent temperature stability at 70 DEG C or below, and can effectively degrade capsular polysaccharide of the KL3 type acinetobacter baumannii.

The invention provides a bifidobacterium longum and longan aril composition capable of synergistically relieving chronic fatigue, the bifidobacterium longum is named as BB36, the preservation number is CGMCC (China General Microbiological Culture Collection Center) NO.34123, and the preservation date is April 8, 2025. By improving the levels of stress hormones and neurotransmitters and reducing the serum inflammation level, the strain significantly improves the chronic fatigue symptom and improves the athletic ability; the invention further develops a bifidobacterium longum and longan aril composition capable of synergistically relieving chronic fatigue, and through compounding of probiotics and longan aril extract, it is found that the probiotics and the longan aril extract can cooperate with each other, and the composition has a synergistic effect in relieving chronic fatigue.

The application provides application of Bacteroides fragilis in improving and / or treating diarrhea. It is proved by different mouse diarrhea model tests that the Bacteroides fragilis ZY-312 with the preservation number of CGMCC No. 10685 or inactivated bacteria thereof have the effects of improving and treating diarrhea. The inactivated bacteria powder of the Bacteroides fragilis has better effects on improving infectious diarrhea or non-infectious diarrhea under different concentration formulations, has no side effects on the body, has a good edible and application prospect, and provides a good product suitable for human consumption for health care and improvement of diarrhea.

The invention relates to the technical field of microorganisms, in particular to an Exiguobacterium aceticum and application thereof. The Exiguobacterium aceticum strain is classified and named as Exiguobacterium aceticum, the strain number is H102, the Exiguobacterium aceticum strain is preserved in the China General Microbiological Culture Collection Center (CGMCC) on December 24, 2025, and the preservation number is CGMCC No.37157. The Exiguobacterium aceticum strain has the advantages that the Exiguobacterium aceticum strain can be used for preparing the Exiguobacterium aceticum strain; the strain has strong saline-alkaline tolerance, drought tolerance and high temperature resistance, and a foundation is provided for colonization of the strain. Meanwhile, the strain has the functional characteristics of producing acetoin, polysaccharide and polyglutamic acid and the like, can effectively provide nutritional ingredients for plant growth and reduce the harm of abiotic stress to the plants, and therefore, the strain has important application value in the aspects of improving saline-alkali soil, improving abiotic stress resistance of the plants, promoting plant growth and the like.

The present application relates to the technical field of probiotics, and particularly relates to a Bifidobacterium breve strain and application of the Bifidobacterium breve strain in prevention or treatment of neurodegenerative diseases and neuroinflammation related to neurodegenerative diseases. Bifidobacterium breve ) BKR006, which is preserved in the China General Microbiological Culture Collection Center (CGMCC) (address: No. 1, Xili Beichen, Chaoyang District, Beijing), and the preservation number is CGMCC No. 36096. The strain in the present application is proved in animal experiments that the strain can not only significantly improve the cognitive function and A beta pathology of AD model animals, but also effectively inhibit neuroinflammation in PD models and improve related cognitive impairment, and has a broad spectrum of neuroprotective effect and good development and application prospect.

The present invention discloses an intestinal microbiota Bacteroides fragilis toxin-neutralizing nanobody and its application. By deeply studying the enterotoxigenic Bacteroides fragilis and the toxin BFT secreted by it in the bodies of patients with colorectal cancer and breast cancer, nanobodies against BFT are expressed by phage display technology; nanobodies with high binding affinity to the antigen are screened out through biopanning technology; a nanobody with the ability to neutralize the toxicity of BFT, also known as Nb2.43, is obtained. The present invention expresses and optimizes to obtain a BFT nanobody protein with high affinity, stability and uniformity, opening up a new field for the treatment of colorectal cancer and breast cancer with nanobodies targeting BFT, and having good research value and application prospects.

The present application relates to the application of Bifidobacterium longum subsp.longum BL21 in the preparation of a preparation for improving hematopoietic dysfunction, wherein the Bifidobacterium longum subsp.longum BL21 is a Bifidobacterium longum subsp.longum BL21 strain with a preservation number of CGMCC No.10452.The present application develops a new microbial strategy for improving hematopoietic dysfunction, and uses the Bifidobacterium longum subsp.longum BL21 in the preparation of a preparation for improving hematopoietic dysfunction.It is found that the Bifidobacterium longum subsp.longum BL21 can increase the number of peripheral blood cells (red blood cells and white blood cells), the content of platelets or the content of hemoglobin, reverse the weight loss caused by hematopoietic dysfunction, and improve the serum inflammatory response and the spleen inflammatory response caused by hematopoietic dysfunction.The present application also provides a new idea for the wide application of the Bifidobacterium longum subsp.longum BL21.

The invention discloses an oxidation-resistant Exiguobacterium sp. LS01 from a marine environment, and belongs to the technical field of microorganisms. The bacterial strain is classified and named as Exiguobacterium oxytolerans, and is preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number is CGMCC No.36750. The invention further discloses a preparation method of the Exiguobacterium oxytolerans strain. The invention further discloses application of the strain and a microbial inoculum of the strain, the strain can stably generate extracellular xanthan gum hydrolase with remarkable xanthan gum degradation activity under the fermentation condition, the viscosity of xanthan gum can be effectively reduced, and a remarkable degradation effect on the xanthan gum is achieved. The strain, the microbial inoculum and the fermentation product thereof can be applied to the fields of xanthan gum degradation and related food, and have wide industrial application prospects.

The invention relates to the field of microorganisms and application, in particular to brevibacillus mat, a microbial agent containing the brevibacillus mat and application of the brevibacillus mat. The invention provides a brevibacillus sschleri strain KY987 which is preserved in the general microbiological center of the China Committee for Culture Collection of Microorganisms, and the preservation number of the brevibacillus sschleri strain KY987 is CGMCC No. 37625. The strain not only has the activity of killing main pathogenic bacteria of soybean root rot, but also has broad-spectrum bactericidal activity on various plant pathogenic bacteria. In addition, the strain also has caenorhabditis elegans killing activity, is easy to grow, and is suitable for realizing large-scale industrial application.

The invention relates to the technical field of biology, and particularly discloses a cronobacter sakazakii nucleic acid aptamer and application thereof in preparation of a biosensor. According to the invention, a nucleic acid aptamer with a DNA sequence as shown in SEQ ID No: 1 is designed for Cronobacter sakazakii MipA protein, and 5'terminal amino is modified. The aptamer can be used for constructing a fluorescence quenching type biosensor, and comprises a fluorescent probe (fluorescent nanoparticles synthesized by citric acid diammonium, thiourea, tetramethyl orthosilicate and cerium dioxide, and a first aptamer modified by carboxyl) and a quenching probe (citric acid reduced gold nanoparticles, a second aptamer modified by sulfydryl, SEQ ID No: 2). Compared with a traditional method, the screening efficiency is remarkably improved, and the detection time is lt; the method has the advantages of high sensitivity, high interference resistance and affinity constant of 13.28 nM, is suitable for rapid monitoring of infant food, and reduces the economic cost by at least 40%.

The application belongs to the technical field of medicine, and particularly relates to a cyclic peptide compound and application thereof in the field of antibiosis. The application discloses a cyclic peptide compound, the structure of which is shown as formula I. The preliminary experiment verifies that the compound has good effects of resisting Acinetobacter baumannii, and has wide application prospects.

The invention relates to the technical field of immunization. The invention discloses parabacteroides dieldrii and parabacteroides goldsteinii, an application of the parabacteroides dieldrii and / or the parabacteroides goldsteinii in preparation of an immunopotentiator of a vaccine, and the immunopotentiator of the vaccine, and particularly discloses the parabacteroides dieldrii and the parabacteroides goldsteinii, the application of the parabacteroides dieldrii and / or the parabacteroides goldsteinii in preparation of the immunopotentiator of the vaccine. The parabacteroides dieldrii and / or the parabacteroides gold can be used as an immunopotentiator, can activate immunity, enhance antibody titer and shorten antibody generation reaction time, and can remarkably promote proliferation of B cells, plasma cells and memory B cell subgroups in a hair growth center.

The application discloses application of antibacterial peptide BMAP-28 and antibiotics in combined preparation of antibacterial drugs and belongs to the technical field of biological medicine. The antibiotics are selected from one or more of the following: ciprofloxacin, gentamicin and cefixime. The application combines the antibacterial peptide BMAP-28 with antibiotics such as ciprofloxacin and gentamicin, finds that the combination has a significant synergistic antibacterial effect on Enterobacter sakazii, can greatly save the dosage of the drug, reduce the toxic side effect and block the evolution process of drug resistance. Through the destruction of the bacterial cell membrane and the assistance of the antibiotic effect, the combination can effectively overcome the multiple drug resistance, widen the antibacterial spectrum and has a wide clinical application prospect.